Abstract:
본 발명은 클리오퀴놀 또는 그 약학적으로 허용가능한 염을 포함하는 자폐증 스펙트럼 장애의 치료용 약학적 조성물에 대한 것이다. 또한 본 발명은 클리오퀴놀 또는 그 약학적으로 허용가능한 염을 포함하는 자폐증 스펙트럼 장애의 개선용 식품 조성물에 대한 것이다.
Abstract:
본 발명은 Shank2 유전자가 결실되고 NMDA 수용체의 기능이 저하된 것을 특징으로 하는 자폐증 모델 형질전환체에 관한 것이다. 본 발명에 따르면 Shank2 유전자의 결실로 인하여 자폐증의 임상적 특징을 나타내는 형질전환마우스를 획득할 수 있고, 자폐증 치료제 후보물질을 선별하는 데 사용할 수 있어 유용하다.
Abstract:
PURPOSE: A composition for diagnosing risk of developing ADHD and a kit are provided to classify a risk group of developing ADHD and to prevent ADHA. CONSTITUTION: A composition for diagnosing ADHA contains a polynucleotide of rs550818 SNP in GIT gene having24926101th C/T base of 17th human chromosome. The composition contains likage disequilibrium site near the rs550818 SNP. A method for predicting risk of developing ADHD comprises: a step of isolating DNAs from a biological sample of a subject; a step of identifying the rs550818 SNP base at 24926101th base site in 17th human chromosome; and a step of determining high risk of developing ADHD in case that the rs550818 SNP allele is C/T.
Abstract:
The present invention relates to an autism model transformant which SHANK2 gene is deleted and the function of a NMDA receptor is reduced. According to the present invention, a transgenic mouse showing clinical features of autism due to a deletion of SHANK2 gene can be obtained and the invention can be used for selecting candidate substances of autism medications.
Abstract:
PURPOSE: A GIT1 gene deficient mouse and a drug screening method using the same are provided to analyze the reason of the attention-deficit hyperactivity disorder and to decipher various kinds of anxiety disorders and diseases. CONSTITUTION: A drug screening method using a GIT1 gene deficient mouse is as follows. A therapeutic agent candidate material of attention-deficit hyperactivity disorder(ADHD) of mammal except for the human is dosed. After the candidate material is administered, an attention-deficit hyperactivity disorder test of mammal except for the human is performed. The candidate material causing the reduction of the attention deficiency hyperactivity disorder is selected.